Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial.

Purpose: A clinical study to characterize renal masses with positron emission tomography/computed tomography (PET/CT) was undertaken.

Patients And Methods: This was an open-label multicenter study of iodine-124 ((124)I) -girentuximab PET/CT in patients with renal masses who were scheduled for resection. PET/CT and contrast-enhanced CT (CECT) of the abdomen were performed 2 to 6 days after intravenous (124)I-girentuximab administration and before resection of the renal mass(es).